5.9
CiteScore
5.9
Impact Factor
Volume 49 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Genetics and Genomics  > 2022  >  49(4): 269-278

Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies

doi: 10.1016/j.jgg.2021.09.009
  •  

    a Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China;

  •  

    b School of Kinesiology, Shanghai University of Sports, Shanghai 200438, China

Funds:

Shanghai Municipal Commission of Science and Technology (20410713200)

“Shuguang Program” supported by Shanghai Education Development Foundation

National Facility for Translational Medicine (Shanghai) (TMSK-2020-102)

National Science Fund for Excellent Young Scholars (31722028)

D Program of China (2018YFA0800600)

Open Project of State Key Laboratory of Natural Medicines

China Pharmaceutical University (SKLNMKF201706, SKLNMZZCX201820)

This work was supported by the following grants to J. L.: National Key R&

National Natural Science Foundation of China (81770797)

and Shanghai Municipal Education Commission (20SG10).

  • Received Date: 2021-07-15
  • Accepted Date: 2021-09-29
  • Rev Recd Date: 2021-09-07
  • Publish Date: 2022-04-30
    Abstract
  • Nonalcoholic steatohepatitis (NASH), an inflammatory subtype of nonalcoholic fatty liver disease, is featured by significantly elevated levels of various proinflammatory cytokines. Among numerous proinflammatory factors that contribute to NASH pathogenesis, the secreted protein, tumor necrosis factor-alpha (TNF-α), plays an essential role in multiple facets of NASH progression and is therefore considered as a potential therapeutic target. In this review, we will first systematically describe the preclinical studies on the biochemical function of TNF-α and its intracellular downstream signaling mechanisms through its receptors. Moreover, we extensively discuss its functions in regulating inflammation, cell death, and fibrosis of liver cells in the pathogenesis of NASH, and the molecular mechanism that TNF-α expression is regulated by NF-κB and other upstream master regulators during NASH progression. As TNF-α is one of the causal factors that remarkably contributes to NASH progression, combination of therapeutic modalities, including TNF-α-based therapies may lead to the resolution of NASH via multiple pathways and thus generate clinical benefits. For translational studies, we summarize recent advances in strategies targeting TNF-α and its signaling pathway, which paves the way for potential therapeutic treatments for NASH in the future.
    • FullText(HTML)
  • loading
    • References(95)
  • Aggarwal, B.B., Gupta, S.C.,Kim, J.H., 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119, 651-665
    Aggarwal, B.B., Kohr, W.J., Hass, P.E., Moffat, B., Spencer, S.A., Henzel, W.J., Bringman, T.S., Nedwin, G.E., Goeddel, D.V.,Harkins, R.N., 1985. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260, 2345-2354
    Alaaeddine, N., Sidaoui, J., Hilal, G., Serhal, R., Abedelrahman, A.,Khoury, S., 2012. TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. Eur Cytokine Netw 23, 107-111
    Aviado, D.M.,Porter, J.M., 1984. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4, 297-307
    Baniasadi, N., Salajegheh, F., Pardakhty, A., Seyedmirzaee, S.M., Hayatbakhsh, M.M., Nikpoor, A.R.,Mohammadi, M., 2015. Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepat Mon 15, e32418
    Barbuio, R., Milanski, M., Bertolo, M.B., Saad, M.J.,Velloso, L.A., 2007. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194, 539-550
    Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., Srinivasan, S., et al., 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733
    Bodmer, J.L., Schneider, P.,Tschopp, J., 2002. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27, 19-26
    Cai, B., Dongiovanni, P., Corey, K.E., Wang, X., Shmarakov, I.O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R.T., et al., 2020. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab 31, 406-421.e407
    Cai, Z., Jitkaew, S., Zhao, J., Chiang, H.C., Choksi, S., Liu, J., Ward, Y., Wu, L.G.,Liu, Z.G., 2014. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 16, 55-65
    Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J.,Shoelson, S.E., 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11, 183-190
    Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., Harrison, S.A., Brunt, E.M.,Sanyal, A.J., 2018. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328-357
    Crespo, J., Cayon, A., Fernandez-Gil, P., Hernandez-Guerra, M., Mayorga, M., Dominguez-Diez, A., Fernandez-Escalante, J.C.,Pons-Romero, F., 2001. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34, 1158-1163
    Daemen, S., Gainullina, A., Kalugotla, G., He, L., Chan, M.M., Beals, J.W., Liss, K.H., Klein, S., Feldstein, A.E., Finck, B.N., et al., 2021. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep 34, 108626
    Daijo, K., Nakahara, T., Inagaki, Y., Nanba, M., Nishida, Y., Uchikawa, S., Kodama, K., Oya, K., Morio, K., Fujino, H., et al., 2020. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. J Gastroenterol Hepatol 35, 1412-1419
    de Mingo, A., de Gregorio, E., Moles, A., Tarrats, N., Tutusaus, A., Colell, A., Fernandez-Checa, J.C., Morales, A.,Mari, M., 2016. Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation. Cell Death Dis 7, e2464
    Doherty, G.M., Jensen, J.C., Alexander, H.R., Buresh, C.M.,Norton, J.A., 1991. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110, 192-198
    Dou, L., Shi, X., He, X.,Gao, Y., 2019. Macrophage Phenotype and Function in Liver Disorder. Front Immunol 10, 3112
    Du, J., Ma, Y.Y., Yu, C.H.,Li, Y.M., 2014. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 20, 569-577
    El-Tahan, R.R., Ghoneim, A.M.,El-Mashad, N., 2016. TNF-α gene polymorphisms and expression. Springerplus 5, 1508
    Fagerberg, L., Hallstrom, B.M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al., 2014. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 13, 397-406
    Feldstein, A.E., Werneburg, N.W., Canbay, A., Guicciardi, M.E., Bronk, S.F., Rydzewski, R., Burgart, L.J.,Gores, G.J., 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40, 185-194
    Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S., Shlomchik, M.J., Coffman, R.L., Candia, A.,Mehal, W.Z., 2016. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 126, 859-864
    Gaul, S., Leszczynska, A., Alegre, F., Kaufmann, B., Johnson, C.D., Adams, L.A., Wree, A., Damm, G., Seehofer, D., Calvente, C.J., et al., 2021. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol 74, 156-167
    Gautheron, J., Gores, G.J.,Rodrigues, C.M.P., 2020. Lytic cell death in metabolic liver disease. J Hepatol 73, 394-408
    Gerges, S.H., Wahdan, S.A., Elsherbiny, D.A.,El-Demerdash, E., 2020. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. Toxicol Appl Pharmacol 401, 115101
    Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al., 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802
    Hemperly, A.,Vande Casteele, N., 2018. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 57, 929-942
    Higuchi, M.,Aggarwal, B.B., 1994. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 152, 3550-3558
    Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H., McDermott, M., 2019. Tumour necrosis factor signalling in health and disease. F1000Res 8, 111
    Ilan, Y., Ben Ya'acov, A., Shabbat, Y., Gingis-Velitski, S., Almon, E.,Shaaltiel, Y., 2016. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol 22, 8760-8769
    Jaco, I., Annibaldi, A., Lalaoui, N., Wilson, R., Tenev, T., Laurien, L., Kim, C., Jamal, K., Wicky John, S., Liccardi, G., et al., 2017. MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. Mol Cell 66, 698-710.e695
    Jaffe, G.J., Dick, A.D., Brezin, A.P., Nguyen, Q.D., Thorne, J.E., Kestelyn, P., Barisani-Asenbauer, T., Franco, P., Heiligenhaus, A., Scales, D., et al., 2016. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375, 932-943
    Ji, Q., Zhang, L., Jia, H.,Xu, J., 2004. Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci 34, 427-436
    Kanuri, G., Spruss, A., Wagnerberger, S., Bischoff, S.C.,Bergheim, I., 2011. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 22, 527-534
    Kazankov, K., Joergensen, S.M.D., Thomsen, K.L., Moeller, H.J., Vilstrup, H., George, J., Schuppan, D.,Groenbaek, H., 2019. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 16, 145-159
    Koca, S.S., Bahcecioglu, I.H., Poyrazoglu, O.K., Ozercan, I.H., Sahin, K.,Ustundag, B., 2008. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 31, 91-98
    Kudo, H., Takahara, T., Yata, Y., Kawai, K., Zhang, W.,Sugiyama, T., 2009. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 51, 168-175
    Li, Q., Li, M., Li, F., Zhou, W., Dang, Y., Zhang, L.,Ji, G., 2020a. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol 258, 112896
    Li, X., Yang, Y.,Ashwell, J.D., 2002. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416, 345-347
    Li, X., Zhang, M., Huang, X., Liang, W., Li, G., Lu, X., Li, Y., Pan, H., Shi, L., Zhu, H., et al., 2020b. Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners. Nat Commun 11, 6364
    Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., Desimone, C., Song, X.Y.,Diehl, A.M., 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343-350
    Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., Fujii, H., Wu, Y., Kam, L.Y., Ji, F., et al., 2019. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 4, 389-398
    Lin, L., Jian, J., Song, C.Y., Chen, F., Ding, K., Xie, W.F.,Hu, P.F., 2020. SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production. FEBS Lett 594, 2965-2974
    Lua, I., Li, Y., Zagory, J.A., Wang, K.S., French, S.W., Sevigny, J.,Asahina, K., 2016. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. J Hepatol 64, 1137-1146
    Ma, L., Gong, H., Zhu, H., Ji, Q., Su, P., Liu, P., Cao, S., Yao, J., Jiang, L., Han, M., et al., 2014. A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model. J Biol Chem 289, 12457-12466
    Majdi, A., Aoudjehane, L., Ratziu, V., Islam, T., Afonso, M.B., Conti, F., Mestiri, T., Lagouge, M., Foufelle, F., Ballenghien, F., et al., 2020. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol 72, 627-635
    Marra, F.,Svegliati-Baroni, G., 2018. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68, 280-295
    Micheau, O.,Tschopp, J., 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190
    Mills, E.L., Harmon, C., Jedrychowski, M.P., Xiao, H., Garrity, R., Tran, N.V., Bradshaw, G.A., Fu, A., Szpyt, J., Reddy, A., et al., 2021. UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab 3, 604-617
    Miura, K., Yang, L., van Rooijen, N., Ohnishi, H.,Seki, E., 2012. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302, G1310-1321
    Mohseni, F., Rashvand, Z., Najafipour, R., Hadizadeh, S.,Moghbelinejad, S., 2016. Evaluating -238 G>A Polymorphism Association in TNF-α Gene with Metabolic Parameters and Nutritional Intakes Among the Iranian NAFLD Patients. Biochem Genet 54, 685-695
    Morton, P.E., Perrin, C., Levitt, J., Matthews, D.R., Marsh, R.J., Pike, R., McMillan, D., Maloney, A., Poland, S., Ameer-Beg, S., et al., 2019. TNFR1 membrane reorganization promotes distinct modes of TNFα signaling. Sci Signal 12
    O'Malley, W.E., Achinstein, B.,Shear, M.J., 1963. ACTION OF BACTERIAL POLYSACCHARIDE ON TUMORS. III. REPEATED RESPONSE OF SARCOMA 37, IN TOLERANT MICE, TO SERRATIA MARCESCENS ENDOTOXIN. Cancer Res 23, 890-895
    Paredes-Turrubiarte, G., Gonzalez-Chavez, A., Perez-Tamayo, R., Salazar-Vazquez, B.Y., Hernandez, V.S., Garibay-Nieto, N., Fragoso, J.M.,Escobedo, G., 2016. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients. Clin Exp Med 16, 193-202
    Radner, H.,Aletaha, D., 2015. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr 165, 3-9
    Romero, F.A., Jones, C.T., Xu, Y., Fenaux, M.,Halcomb, R.L., 2020. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem 63, 5031-5073
    Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Moeller, H.J., et al., 2019. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol 71, 1012-1021
    Satapathy, S.K., Garg, S., Chauhan, R., Sakhuja, P., Malhotra, V., Sharma, B.C.,Sarin, S.K., 2004. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99, 1946-1952
    Satapathy, S.K., Sakhuja, P., Malhotra, V., Sharma, B.C.,Sarin, S.K., 2007. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22, 634-638
    Schramm, C., Schneider, A., Marx, A.,Lohse, A.W., 2008. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 46, 1369-1371
    Schuster, S., Cabrera, D., Arrese, M.,Feldstein, A.E., 2018. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 15, 349-364
    Song, K., Kwon, H., Han, C., Chen, W., Zhang, J., Ma, W., Dash, S., Gandhi, C.R.,Wu, T., 2020. Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis. Hepatology 72, 72-87
    Sun, W., Wu, Y., Zheng, M., Yang, Y., Liu, Y., Wu, C., Zhou, Y., Zhang, Y., Chen, L.,Li, H., 2020. Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor. J Med Chem 63, 8146-8156
    Sun, X., Zhu, S., Dong, X., Strand-Amundsen, R.J., Tonnessen, T.I.,Yang, R., 2021. Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis. Biomed Pharmacother 137, 111392
    Tasci, I., Dogru, T., Ercin, C.N., Erdem, G.,Sonmez, A., 2008. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28, 266-267;author reply 267-268
    Tokushige, K., Takakura, M., Tsuchiya-Matsushita, N., Taniai, M., Hashimoto, E.,Shiratori, K., 2007. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46, 1104-1110
    Tomita, K., Tamiya, G., Ando, S., Ohsumi, K., Chiyo, T., Mizutani, A., Kitamura, N., Toda, K., Kaneko, T., Horie, Y., et al., 2006. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55, 415-424
    Tosello-Trampont, A.C., Landes, S.G., Nguyen, V., Novobrantseva, T.I.,Hahn, Y.S., 2012. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem 287, 40161-40172
    Valenti, L., Fracanzani, A.L., Dongiovanni, P., Santorelli, G., Branchi, A., Taioli, E., Fiorelli, G.,Fargion, S., 2002. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122, 274-280
    Van Wagner, L.B., Koppe, S.W., Brunt, E.M., Gottstein, J., Gardikiotes, K., Green, R.M.,Rinella, M.E., 2011. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 10, 277-286
    Wandrer, F., Liebig, S., Marhenke, S., Vogel, A., John, K., Manns, M.P., Teufel, A., Itzel, T., Longerich, T., Maier, O., et al., 2020. TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis 11, 212
    Wang, J.K., Feng, Z.W., Li, Y.C., Li, Q.Y.,Tao, X.Y., 2012. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 27, 670-676
    Wang, P.X., Ji, Y.X., Zhang, X.J., Zhao, L.P., Yan, Z.Z., Zhang, P., Shen, L.J., Yang, X., Fang, J., Tian, S., et al., 2017. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med 23, 439-449
    Wang, X., Cai, B., Yang, X., Sonubi, O.O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U.B., Sandhu, J., et al., 2020. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metab 31, 969-986.e967
    Wang, X., Zheng, Z., Caviglia, J.M., Corey, K.E., Herfel, T.M., Cai, B., Masia, R., Chung, R.T., Lefkowitch, J.H., Schwabe, R.F., et al., 2016. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab 24, 848-862
    Wen, W.X., Lee, S.Y., Siang, R.,Koh, R.Y., 2017. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Adv Ther 34, 1245-1269
    Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M.,Ahmed, A., 2015. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547-555
    Wree, A., McGeough, M.D., Inzaugarat, M.E., Eguchi, A., Schuster, S., Johnson, C.D., Pena, C.A., Geisler, L.J., Papouchado, B.G., Hoffman, H.M., et al., 2018. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. Hepatology 67, 736-749
    Wu, X., Poulsen, K.L., Sanz-Garcia, C., Huang, E., McMullen, M.R., Roychowdhury, S., Dasarathy, S.,Nagy, L.E., 2020. MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis. J Hepatol 73, 616-627
    Wu, Z., Xu, J., Tan, J., Song, Y., Liu, L., Zhang, F., Zhang, Y., Li, X., Chi, Y.,Liu, Y., 2019. Mesenteric adipose tissue B lymphocytes promote local and hepatic inflammation in non-alcoholic fatty liver disease mice. J Cell Mol Med 23, 3375-3385
    Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al., 2018. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol 68, 773-782
    Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A.,Nader, F., 2019a. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 71, 793-801
    Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L.,Wymer, M., 2016. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73-84
    Younossi, Z.M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q.M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P.N., et al., 2019b. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184-2196
    Zahran, W.E., Salah El-Dien, K.A., Kamel, P.G.,El-Sawaby, A.S., 2013. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. Indian J Clin Biochem 28, 141-146
    Zein, C.O., Lopez, R., Fu, X., Kirwan, J.P., Yerian, L.M., McCullough, A.J., Hazen, S.L.,Feldstein, A.E., 2012. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 56, 1291-1299
    Zein, C.O., Yerian, L.M., Gogate, P., Lopez, R., Kirwan, J.P., Feldstein, A.E.,McCullough, A.J., 2011. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54, 1610-1619
    Zeng, T., Zhang, C.L., Zhao, X.L.,Xie, K.Q., 2014. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 26, 646-653
    Zhang, Q., Cui, F., Fang, L., Hong, J., Zheng, B.,Zhang, J.Z., 2013. TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J Mol Cell Biol 5, 85-98
    Zhang, W., Kudo, H., Kawai, K., Fujisaka, S., Usui, I., Sugiyama, T., Tsukada, K., Chen, N.,Takahara, T., 2010. Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem Biophys Res Commun 391, 1731-1736
    Zhang, Q., Lenardo, M.J.,Baltimore, D., 2017. 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell 168, 37-57
    Zhang, T., Hu, J., Wang, X., Zhao, X., Li, Z., Niu, J., Steer, C.J., Zheng, G.,Song, G., 2019a. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway. J Hepatol 70, 87-96
    Zhang, X., Fan, L., Wu, J., Xu, H., Leung, W.Y., Fu, K., Wu, J., Liu, K., Man, K., Yang, X., et al., 2019b. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. J Hepatol 71, 163-174
    Zhao, P., Sun, X., Chaggan, C., Liao, Z., In Wong, K., He, F., Singh, S., Loomba, R., Karin, M., Witztum, J.L., et al., 2020. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367, 652-660
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF

    Article Metrics

    Article views (336) PDF downloads (32) Cited by ()
    Proportional views
    Related

    Editorial Office

    Journal of Genetics and Genomics

    京ICP备09063187号-7

    No.1, West Beichen Road, Chaoyang District, Beijing 100101, P.R.China

    +86-10-64806528+86-10-64807786jgg@genetics.ac.cn

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return